Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi(Memorial Sloan Kettering Cancer Center), Julien Mazières(Hôpital Larrey), David Planchard(Institut Gustave Roussy), Thomas E. Stinchcombe(University of North Carolina at Chapel Hill), Grace K. Dy(Roswell Park Comprehensive Cancer Center), Scott Antonia(Moffitt Cancer Center), Leora Horn(Vanderbilt-Ingram Cancer Center), H. Léna(Centre Hospitalier Universitaire de Rennes), Elisa Minenza, B. Mennecier(Hôpital Civil, Strasbourg), Gregory A. Otterson(The Ohio State University), Luis T. Campos(Hematology Oncology Consultants), David R. Gandara(University of California, Davis), Benjamin Levy(Mount Sinai Beth Israel), Suresh Nair(Lehigh Valley Hospital-Pocono), Gérard Zalcman(Centre Hospitalier Universitaire de Caen Normandie), Jürgen Wolf, Pierre‐Jean Souquet(Hospices Civils de Lyon), Editta Baldini, Federico Cappuzzo(Ospedale di Livorno), C. Chouaïd(Hôpital Intercommunal de Créteil), Afshin Dowlati(University Hospitals of Cleveland), Rachel E. Sanborn(Providence Portland Medical Center), Ariel López-Chávez(University of Miami), Christian Grohé(Evangelische Lungenklinik Berlin), Rudolf M. Huber(German Center for Lung Research), Christopher Harbison(Bristol-Myers Squibb (United States)), Christine Baudelet(Bristol-Myers Squibb (United States)), Brian Lestini(Bristol-Myers Squibb (United States)), Suresh S. Ramalingam(Emory University)
Cited by 1,427
Abstract
Related Papers
No related papers found
Powered by citation graph analysis